The Australian Mohs database, part II - Periocular basal cell carcinoma outcome at 5-year follow-up
Date
2004
Authors
Malhotra, R.
Huilgol, S.
Huynh, N.
Selva-Nayagam, D.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Ophthalmology (Rochester, Minn.), 2004; 111(4):631-636
Statement of Responsibility
Conference Name
Abstract
<h4>Objective</h4>To report the outcome with 5-year strict follow-up (only cases where 5-year follow-up is available) of all patients with periocular basal cell carcinoma (BCC) treated with Mohs' micrographic surgery (MMS) in Australia between 1993 and 1996.<h4>Design</h4>Prospective, noncomparative, multicenter, interventional case series.<h4>Methods</h4>A prospective series of 819 patients, undergoing MMS for periocular BCC over a 3-year period (1993-1996).<h4>Inclusion criteria</h4>Periocular BCC referred for MMS.<h4>Main outcome measures</h4>Recurrence, site, size, prior occurrence, defect size, histologic subtype, and presence of perineural invasion.<h4>Results</h4>Eight hundred nineteen patients had 257 (54%) lower eyelid, 195 (41%) medial canthus, and 22 (5%) upper eyelid BCCs. The most common histologic subtypes were nodulocystic (43%) and infiltrating (30%) (P = 0.0003). Sixty-eight percent were primary and 32% were recurrent tumors. Five-year follow-ups for cases between 1993 and 1996 were available in 347 (42%) cases. There were 7 recurrences (2.0%; exact 95% confidence interval [CI]: 0.82%-4.1%), 5 of which were at the medial canthus and all of which were previously recurrent, with up to 3 recurrences before MMS. Previous recurrence (P<0.0001), infiltrating (5) or superficial (2) histologic subtype (P = 0.0882), and medial canthal site were the main predictors of recurrence after MMS. There were no recurrences for primary BCC, and the 5-year recurrence for previously recurrent BCC was 7.8% (exact 95% CI: 3.2%-15.4%).<h4>Conclusion</h4>The Australian MMS database is the largest prospective nationwide series of periocular BCC managed by MMS. The strict 5-year recurrence rates of 0% and 7.8% for primary and recurrent tumors, respectively, confirm MMS as the treatment of choice for periocular BCC.